Suven Life Sciences is currently trading at Rs. 218.20, up by 5.40 points or 2.54% from its previous closing of Rs. 212.80 on the BSE.
The scrip opened at Rs. 215.15 and has touched a high and low of Rs. 222.00 and Rs. 212.15 respectively. So far 61177 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 157.15 on 03-Sep-2014.
Last one week high and low of the scrip stood at Rs. 229.65 and Rs. 210.10 respectively. The current market cap of the company is Rs. 2788.76 crore.
The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 7.49% and 33.06% respectively.
Suven Life Sciences has commenced phase 1 clinical trial of NCE SUVN-D4010 in USA. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s disease and other dementias.
The company submitted Investigational New Drug Application (IND) to US FDA to conduct Phase-1 clinical trial for Cognition in Alzheimer’s disease, under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an IND number 126099.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
